associated with Tbx20 and Cdh11 are transactivated by Twist1 in an E-box dependent manner and are directly bound by Twist1 in mouse ECC mesenchymal cells. Additional Twist1 candidate genes were identified through Affymetrix microarray analysis of MC3T3-E1 cells treated with control siRNA or Twist1 siRNA. Loss of Twist1 resulted in decreased expression of genes associated with cell proliferation, migration, and ECM components. E-box consensus sites were identified within ECRs of Semaphorin3C, Gadd45a, and Rab39b. All three ECRs are directly bound by Twist1 in mouse ECC mesenchymal cells. These studies identified Twist1 direct transcriptional targets promoting cell proliferation and migration in ECC mesenchymal cells. Therefore, these Twist1 transcriptional target genes likely contribute to maintenance and expansion of valve progenitor cells during early stages of valve development. T-box genes (e.g. Ntla and Tbx16) encode transcription factors that govern critical aspects of early embryonic development. We have performed promoter ChIP-on-chip microarrays for Ntla (Morley et al 2009) and Tbx16. Based on these data, we extracted 35 targets that were potentially co-regulated by Ntla and Tbx16, based on cooccupation of upstream genomic regions. We performed an in situ hybridization screen using ntla, spt (Tbx16 mutant) and ntl; spt mutant embryos. A subset of these targets showed mutual regulation by Ntla and Tbx16 and we confirmed these observations using ntl and/or Tbx16 morpholinos. Subsequently, we tested this subset for direct regulation by Tbx16 and Ntla by protein synthesis inhibition. We confirmed binding of Ntla and Tbx16 to the genomic regions identified by ChIP in EMSA and yeast 1-hybrid assays. To assay for function we used luciferase and mCherry reporter assays in vivo. Here we will present the data for each individual target tested. We used this information and previously published data to build a GRN regulatory demarcating overlapping and non-overlapping targets of Tbx16 and Ntla in different aspects of mesoderm development. The C. elegans T-box gene tbx-2 is necessary for pharyngeal muscle development and differentiation of a subset of neurons. We are interested in understanding how tbx-2 is regulated. In wild-type animals, a tbx-2::gfp reporter is expressed in pharyngeal precursors and in several neurons. Using an RNAi-based screen to identify transcription factors regulating tbx-2 expression, we have identified the NF-Y complex and TBX-2 itself as negative regulators of tbx-2. NF-Y is a heterotrimeric CCAAT-binding complex consisting of A, B and C subunits, and reduction of the NF-Y subunits nfya-1, nfyb-1, or nfyc-1 by RNAi or using mutants results in ectopic tbx-2::gfp expression in hypodermal seam cells and gut. Mutation of two CCAAT sites in the tbx-2 promoter results in a similar pattern of ectopic tbx-2::gfp expression, suggesting that NF-Y directly represses the tbx-2 promoter. Reduction of tbx-2 by RNAi or using a hypomorphic tbx-2 mutant also results in ectopic tbx-2::gfp expression in seam cells and gut. While tbx-2 expression has not been previously observed in these tissues, recent whole genome RNA profiling studies suggest tbx-2 is broadly expressed. We find that mutation of a T-box factor binding site in the tbx-2 promoter results in ectopic tbx-2::gfp expression, consistent with direct autoregulation. We have previously suggested that TBX-2 is a SUMOylation-dependent transcriptional repressor, and we find that RNAi of SUMOylation components results in ectopic tbx-2::gfp expression in seam cells and gut, and in additional tissues. We suggest the tbx-2 promoter is directly repressed by TBX-2 and perhaps other SUMOylation dependent transcription factors. T-box transcription factors are key developmental regulators, but despite their importance, little is known about how these proteins are regulated. Based on a previous work, we hypothesize the C. elegans Tbox factor TBX-2 functions as a SUMO-dependent transcriptional repressor. Here we demonstrate TBX-2 function depends on SUMOylation in vivo. Further, we show that TBX-2 interaction with SUMOylation enzymes is mediated by two consensus SUMOylation sites located in the T-box DNA-binding domain and near the TBX-2 Cterminus, respectively. TBX-2 is SUMOylated upon co-transfection with human SUMO-1 protein in COS-1 cells. Mutation of the SUMOattachment lysine within the C-terminal SUMO consensus site has a significant effect on total TBX-2 SUMOylation, whereas mutation of the T-box site lysine has a more modest effect on SUMOylation. In comparison, a more severe mutation converting these SUMO consensus sites to all alanines completely eliminated SUMOylation. To examine the effect of SUMOylation on TBX-2 function, we compared wild-type TBX-2 to the mutant in which the SUMOconsensus sites were mutated to alanines. SUMOylation is not necessary for normal TBX-2 nuclear localization in either C. elegans or COS-1 cells. Likewise, while wild-type TBX-2 fused to the Gal4 DNA-binding domain can repress a Gal4 binding-site containing reporter, SUMOylation is not necessary for this repression. We suggest that SUMOylation may affect TBX-2 DNA-binding or interaction with other factors bound to target promoters. We are currently developing an assay to determine if TBX-2 is a SUMO-dependent repressor using a TBX-2 regulated promoter in C. elegans. 
